Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAY H SANDBERG

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1548293483
CMS profile
206406
Location
TROY, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$4,642.35

170 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,501.36 166
Consulting Fee $2,040.00 2
Education $100.99 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAY H SANDBERG

NPI 1548293483 · CMS profile ID 206406

Allopathic & Osteopathic Physicians / Internal Medicine

TROY, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1548293483?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAY H SANDBERG, NPI 1548293483, CMS profile ID 206406. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548293483?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JAY H SANDBERG, NPI 1548293483, CMS profile ID 206406. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548293483?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JAY H SANDBERG, NPI 1548293483, CMS profile ID 206406, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–170 of 170 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1548293483?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

170 matching records · $4,642.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 170 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–170 of 170.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $13.2502/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833514775 CMS
Daiichi Sankyo Inc. $11.9902/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836261557 CMS
AbbVie Inc. $19.6002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795946979 CMS
AstraZeneca Pharmaceuticals LP $64.0502/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830016185 CMS
AstraZeneca Pharmaceuticals LP $12.9802/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830005529 CMS
Amgen Inc. $11.3802/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825393079 CMS
Esperion Therapeutics, Inc. $15.0602/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838394957 CMS
SANOFI-AVENTIS U.S. LLC $14.8502/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843433373 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.1201/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763689748 CMS
Lilly USA, LLC $1.0001/28/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819158245 CMS
Lilly USA, LLC $12.7101/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818561203 CMS
Medicure Pharma Inc. $22.9501/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827906829 CMS
Novo Nordisk Inc $10.9601/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811017203 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $9.6101/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763689750 CMS
Lilly USA, LLC $14.0401/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819109979 CMS
Lilly USA, LLC $13.3701/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818552667 CMS
Lilly USA, LLC $11.8601/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819109987 CMS
SANOFI-AVENTIS U.S. LLC $11.9501/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843433349 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2501/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850002789 CMS
Genentech USA, Inc. $15.4401/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835923513 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,909.53 128
PY2020 $3,548.06 126
PY2021 $4,642.35 170
PY2022 $4,525.51 156
PY2023 $2,212.85 133
PY2024 $5,202.68 117
PY2025 $1,969.47 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,509,593.96 142
PY2024 Principal investigator $2,002,417.92 105
PY2023 Principal investigator $1,345,098.03 83
PY2022 Principal investigator $1,273,184.65 79
PY2021 Recipient $138.20 1
PY2021 Principal investigator $596,006.29 111
PY2020 Principal investigator $137,699.34 45
PY2019 Principal investigator $390,285.70 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

142 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $53,948.30 12/22/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137247
Principal investigator 1 ModernaTX, Inc. $805.84 12/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998249
Principal investigator 1 ModernaTX, Inc. $4,861.56 12/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998261
Principal investigator 1 ModernaTX, Inc. $59,094.75 12/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998273
Principal investigator 1 ModernaTX, Inc. $2,880.00 12/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998279
Principal investigator 1 Genentech, Inc. $8,000.00 12/17/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RESEARCH
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211618314
Principal investigator 1 PFIZER INC. $31,082.15 12/12/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228744446
Principal investigator 1 SANOFI US SERVICES INC. $19,917.90 12/08/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226137237
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220784583
Principal investigator 1 ModernaTX, Inc. $4,320.00 11/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998207
Principal investigator 1 ModernaTX, Inc. $5,435.76 11/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998229
Principal investigator 1 ModernaTX, Inc. $2,417.52 11/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998259
Principal investigator 1 PFIZER INC. $26,824.60 11/26/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228714320
Principal investigator 1 ModernaTX, Inc. $715.00 11/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998237
Principal investigator 1 Genentech, Inc. $7,614.00 11/21/2025 Non-covered Recipient Entity
OAKLAND MEDICAL RESEARCH CENTER
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211633252
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 11/19/2025 Non-covered Recipient Entity
J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220784585
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 11/19/2025 Non-covered Recipient Entity
J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220784587
Principal investigator 1 Janssen Research & Development, LLC $12,568.00 11/19/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234319
Principal investigator 1 SANOFI US SERVICES INC. $110,597.75 11/10/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137196
Principal investigator 1 Janssen Research & Development, LLC $27,460.00 11/07/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234237
Principal investigator 1 Genentech, Inc. $25,295.00 11/04/2025 Non-covered Recipient Entity
OAKLAND MEDICAL RESEARCH CENTER
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211633248
Principal investigator 1 PFIZER INC. $382.76 11/04/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228714318
Principal investigator 1 Janssen Research & Development, LLC $6,042.00 11/03/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234276
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 11/01/2025 Non-covered Recipient Entity
J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220784575
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 11/01/2025 Non-covered Recipient Entity
J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220784577
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220784579
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
J.H.S.D.O.P.C. DBA OAKLAND MEDICAL RESEARCH CENTER
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220784581
Principal investigator 1 PFIZER INC. $79,566.30 10/31/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228740359
Principal investigator 1 ModernaTX, Inc. $5,512.32 10/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998251
Principal investigator 1 ModernaTX, Inc. $14,760.00 10/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998277
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,470.00 10/19/2025 Non-covered Recipient Entity
OAKLAND MEDICAL CENTER
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190306987
Principal investigator 1 PFIZER INC. $8,309.28 10/08/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228755005
Principal investigator 1 ModernaTX, Inc. $5,110.38 09/29/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998245
Principal investigator 1 ModernaTX, Inc. $1,611.68 09/29/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998255
Principal investigator 1 ModernaTX, Inc. $17,280.00 09/29/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998291
Principal investigator 1 PFIZER INC. $1,913.80 09/24/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228751701
Principal investigator 1 Janssen Research & Development, LLC $6,824.00 09/19/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234245
Principal investigator 1 GlaxoSmithKline, LLC. $8,000.00 09/17/2025 Non-covered Recipient Entity
JHSDOPC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192113908
Principal investigator 1 GlaxoSmithKline, LLC. $2,125.00 09/17/2025 Non-covered Recipient Entity
JHSDOPC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192113914
Principal investigator 1 PFIZER INC. $13,351.80 09/03/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228749681
Principal investigator 1 PFIZER INC. $1,913.80 09/03/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228753611
Principal investigator 1 ModernaTX, Inc. $6,124.80 08/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998199
Principal investigator 1 ModernaTX, Inc. $1,440.00 08/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998209
Principal investigator 1 ModernaTX, Inc. $2,417.52 08/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998225
Principal investigator 1 ModernaTX, Inc. $18,040.96 08/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998269
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,046.31 08/27/2025 Non-covered Recipient Entity
OAKLAND MEDICAL CENTER
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185543745
Principal investigator 1 Janssen Research & Development, LLC $15,211.00 08/25/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234298
Principal investigator 1 SANOFI US SERVICES INC. $58,712.59 08/18/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137654
Principal investigator 1 PFIZER INC. $33,275.76 08/05/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228767412
Principal investigator 1 SANOFI US SERVICES INC. $4,951.40 08/04/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137637
Principal investigator 1 ModernaTX, Inc. $1,569.48 07/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998219
Principal investigator 1 Janssen Research & Development, LLC $6,806.00 07/23/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234268
Principal investigator 1 Genentech, Inc. $5,622.00 07/22/2025 Non-covered Recipient Entity
OAKLAND MEDICAL RESEARCH CENTER
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211633244
Principal investigator 1 SANOFI US SERVICES INC. $73,376.39 07/21/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137559
Principal investigator 1 PFIZER INC. $56,042.00 07/17/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228772693
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $14,869.00 07/16/2025 Non-covered Recipient Entity
Oakland Medical Center
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225407356
Principal investigator 1 Genentech, Inc. $9,269.00 07/02/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RESEARCH
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211618309
Principal investigator 1 SANOFI US SERVICES INC. $9,488.70 07/02/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137568
Principal investigator 1 ModernaTX, Inc. $8,640.00 06/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998221
Principal investigator 1 ModernaTX, Inc. $4,363.92 06/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998253
Principal investigator 1 ModernaTX, Inc. $47,357.52 06/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998257
Principal investigator 1 PFIZER INC. $178,882.80 06/26/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228786930
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,672.58 06/24/2025 Non-covered Recipient Entity
Oakland Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235995032
Principal investigator 1 Janssen Research & Development, LLC $10,676.00 06/23/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234254
Principal investigator 1 Janssen Research & Development, LLC $7,884.00 06/20/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234221
Principal investigator 1 ModernaTX, Inc. $58,633.12 06/18/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998211
Principal investigator 1 ModernaTX, Inc. $4,842.42 06/18/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998287
Principal investigator 1 ModernaTX, Inc. $16,560.00 06/18/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998289
Principal investigator 1 SANOFI US SERVICES INC. $24,409.85 06/16/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137526
Principal investigator 1 Genentech, Inc. $11,423.00 06/02/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RE
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211618279
Principal investigator 1 PFIZER INC. $18,784.00 05/30/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228763321
Principal investigator 1 ModernaTX, Inc. $2,417.52 05/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998263
Principal investigator 1 ModernaTX, Inc. $5,129.52 05/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998265
Principal investigator 1 ModernaTX, Inc. $42,120.00 05/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998293
Principal investigator 1 SANOFI US SERVICES INC. $14,613.40 05/27/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137488
Principal investigator 1 Janssen Research & Development, LLC $12,753.00 05/21/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234303
Principal investigator 1 PFIZER INC. $2,283.94 05/21/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228771330
Principal investigator 1 PFIZER INC. $15,947.74 05/19/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228706719
Principal investigator 1 PFIZER INC. $15,947.74 05/19/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228762176
Principal investigator 1 SANOFI US SERVICES INC. $38,838.86 05/19/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137544
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,120.00 05/16/2025 Non-covered Recipient Entity
OAKLAND MEDICAL CENTER
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185543747
Principal investigator 1 PFIZER INC. $31,082.86 05/07/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228783251
Principal investigator 1 Genentech, Inc. $846.00 05/06/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RE
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211618270
Principal investigator 1 Genentech, Inc. $3,003.00 05/06/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RE
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211618274
Principal investigator 1 Genentech, Inc. $1,964.00 04/30/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RESEARCH
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211618305
Principal investigator 1 ModernaTX, Inc. $9,720.00 04/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998223
Principal investigator 1 ModernaTX, Inc. $1,339.80 04/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998227
Principal investigator 1 ModernaTX, Inc. $25,560.00 04/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998281
Principal investigator 1 ModernaTX, Inc. $3,904.56 04/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998285
Principal investigator 1 Janssen Research & Development, LLC $18,506.00 04/23/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234261
Principal investigator 1 SANOFI US SERVICES INC. $28,766.70 04/21/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137440
Principal investigator 1 PFIZER INC. $9,815.64 04/17/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228780185
Principal investigator 1 PFIZER INC. $1,724.08 04/16/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228706721
Principal investigator 1 PFIZER INC. $1,724.08 04/16/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228770890
Principal investigator 1 SANOFI US SERVICES INC. $41,809.31 04/14/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137422
Principal investigator 1 PFIZER INC. $6,896.32 04/09/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228706723
Principal investigator 1 PFIZER INC. $6,896.32 04/09/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228761436
Principal investigator 1 PFIZER INC. $10,344.48 04/08/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228708092
Principal investigator 1 PFIZER INC. $10,344.48 04/08/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228760185
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 04/02/2025 Non-covered Recipient Entity
JHSDOPC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192113919
Principal investigator 1 GlaxoSmithKline, LLC. $34,496.80 04/02/2025 Non-covered Recipient Entity
JHSDOPC
A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T No dispute reported 06/30/2026 1192113923
Principal investigator 1 SANOFI US SERVICES INC. $3,500.00 04/02/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137390
Principal investigator 1 SANOFI US SERVICES INC. $14,919.60 04/02/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137403
Principal investigator 1 Genentech, Inc. $2,922.00 03/28/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RESEARCH
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211618303
Principal investigator 1 ModernaTX, Inc. $36,000.00 03/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998215
Principal investigator 1 ModernaTX, Inc. $805.84 03/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998241
Principal investigator 1 ModernaTX, Inc. $4,995.54 03/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998271
Principal investigator 1 ModernaTX, Inc. $15,595.58 03/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998275
Principal investigator 1 SANOFI US SERVICES INC. $65,608.15 03/24/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137339
Principal investigator 1 Genentech, Inc. $1,964.00 03/21/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RESEARCH
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211618295
Principal investigator 1 Janssen Research & Development, LLC $13,299.00 03/21/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234229
Principal investigator 1 PFIZER INC. $677.05 03/18/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228774726
Principal investigator 1 PFIZER INC. $793.65 03/18/2025 Non-covered Recipient Entity
Oakland Medical Research
A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE No dispute reported 06/30/2026 1228786067
Principal investigator 1 Janssen Research & Development, LLC $21,044.00 03/17/2025 Non-covered Recipient Entity
J H S D O P C
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175362613
Principal investigator 1 Novartis Pharmaceuticals Corporation $67,656.12 03/10/2025 Non-covered Recipient Entity
OAKLAND MEDICAL RESEARCH CENTER
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190306989
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $2,134.54 03/08/2025 Non-covered Recipient Entity
OAKLAND MEDICAL RESEARCH
A PHASE 3, MULTICENTER, LONG-TERM, EXTENSION STUDY OF THE SAFETY AND EFFICACY OF AVP-786 (DEUTERATED [D6] DEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335659
Principal investigator 1 SANOFI US SERVICES INC. $64,457.50 03/04/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137401
Principal investigator 1 Genentech, Inc. $2,895.00 03/03/2025 Non-covered Recipient Entity
OAKLAND MEDICAL RESEARCH CENTER
Transmission Study household No dispute reported 06/30/2026 1211633240
Principal investigator 1 Genentech, Inc. $9,748.00 02/28/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RESEARCH
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211618286
Principal investigator 1 ModernaTX, Inc. $39,799.08 02/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998197
Principal investigator 1 ModernaTX, Inc. $2,417.52 02/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998231
Principal investigator 1 ModernaTX, Inc. $5,799.42 02/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998243
Principal investigator 1 ModernaTX, Inc. $49,014.68 02/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998247
Principal investigator 1 ModernaTX, Inc. $2,717.88 02/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998267
Principal investigator 1 ModernaTX, Inc. $25,560.00 02/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998297
Principal investigator 1 Janssen Research & Development, LLC $18,117.00 02/19/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234313
Principal investigator 1 PFIZER INC. $6,886.50 02/12/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228768941
Principal investigator 1 SANOFI US SERVICES INC. $11,357.01 02/10/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226137317
Principal investigator 1 Genentech, Inc. $982.00 02/05/2025 Non-covered Recipient Entity
JHSDOPC DBA OAKLAND MEDICAL RESEARCH
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211618299
Principal investigator 1 SANOFI US SERVICES INC. $41,737.70 02/04/2025 Non-covered Recipient Entity
Elias Research Associates LLC
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226137288
Principal investigator 1 ModernaTX, Inc. $4,287.36 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998195
Principal investigator 1 ModernaTX, Inc. $2,417.52 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998201
Principal investigator 1 ModernaTX, Inc. $1,722.60 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998203
Principal investigator 1 ModernaTX, Inc. $42,330.86 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998205
Principal investigator 1 ModernaTX, Inc. $2,430.78 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998213
Principal investigator 1 ModernaTX, Inc. $1,080.00 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998217
Principal investigator 1 ModernaTX, Inc. $86,231.34 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998233
Principal investigator 1 ModernaTX, Inc. $49,748.85 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998235
Principal investigator 1 ModernaTX, Inc. $5,512.32 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998239
Principal investigator 1 ModernaTX, Inc. $14,400.00 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998283
Principal investigator 1 ModernaTX, Inc. $17,823.52 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252998295
Principal investigator 1 Janssen Research & Development, LLC $17,013.00 01/22/2025 Non-covered Recipient Entity
Jhsdopc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175234288